

31st January, 2020

BSE Limited

1st Floor, New Trading Wing, Rotunda Bldg, P.J. Towers, Dalal Street, Fort, Mumbai- 400 001

National Stock Exchange of India Ltd.,

Exchange Plaza, 5th Floor, Plot No. C/1, G. Block, Bandra-Kurla Complex, Mumbai – 400 051.

Dear Sir / Madam,

BSE SCRIP CODE – 500302, 912460 NSE SYMBOL – PEL

Sub: Intimation of Conference Call with Investors/ Analysts under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the details of the Conference Call with investors/analysts.

Kindly take the above on record.

Thanking you,

Yours truly, For **Piramal Enterprises Limited**

Bipin Singh Company Secretary

Encl.: a/a



Piramal Enterprises Limited

Third Quarter and Nine Months ended 31st Dec 2019 Earnings Conference Call

Mumbai, India, January 31, 2020: Piramal Enterprises Limited ('PEL', NSE: PEL, BSE: 500302,912460) will be hosting a conference call of investors / analysts with Chairman & its Management team on Tuesday, 4th February 2020 at 6:30 PM (IST) to discuss Q3 & 9M FY2020 Results.

The dial-in numbers for the call are as under:

Event	Location & Time	Telephone Number
Conference call on 4 th Feb, 2020		+91 22 6280 1264 / +91 22 7115 8165 (Primary Number)
	India – 6:30 PM IST	+91 70456 71221 (Local Number)
		1800 120 1221 / 1800 266 1221 (Toll free number)
	USA – 8:00 AM	Toll free number
	(Eastern Time – New York)	18667462133
	UK – 1:00 PM	Toll free number
	(London Time)	08081011573
	Singapore – 9:00 PM	Toll free number
	(Singapore Time)	8001012045
	Hong Kong – 9:00 PM	Toll free number
	(Hong Kong Time)	800964448
For online	https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=108001&lin kSecurityString=36ec6ed4	
registration		

For further information, please contact:

For Investors:

Hitesh Dhaddha Chief Investor Relations Officer Piramal Enterprises Limited Contact: +91 22 3046 6306 investor.relations@piramal.com

About Piramal Enterprises Ltd.

Piramal Enterprises Limited (PEL) is one of India's largest diversified companies, with a presence in Financial Services and Pharmaceuticals. PEL's consolidated revenues were ~US\$1.9 billion in FY2019, with around ~40% of revenues generated from outside India.

In Financial Services, Piramal Capital & Housing Finance Limited (PCHFL), wholly owned subsidiary of Piramal Enterprises Limited (the flagship company of Piramal Group), is registered as a housing finance company with National Housing Bank (NHB) and engaged in various financial services businesses. It provides both wholesale and retail funding opportunities across sectors. In real estate, the platform provides housing finance and other financing solutions across the entire capital stack such as structured debt, construction finance, flexi lease rental discounting etc. The wholesale business in non-real estate sector includes separate verticals- Corporate Finance (CFG) and Emerging Corporate Lending (ECL). CFG provides customized funding solutions to companies across sectors such as infrastructure, renewable energy, roads, industrials, auto components etc. while ECL focuses on lending towards, Small and Medium Enterprises (SMEs). PCHFL's group companies provides customized strategies for institutional and retail investors such as Mumbai Redevelopment Fund and Apartment Fund (through Piramal Fund Management) and strategic partnerships with leading global pension funds such as CPPIB, APG and Ivanhoe Cambridge. The division has also launched a Distressed Asset Investing platform with Bain Capital Credit - IndiaRF that will invest in equity and/or debt in assets across sectors (other than real estate) to drive restructuring with active participation in turnaround. PEL also has equity investments in Shriram Group, a leading financial conglomerate in India.

In Pharma, through end-to-end manufacturing capabilities across 13 global facilities and a large global distribution network to over 100 countries, PEL sells a portfolio of niche differentiated pharma products and provides an entire pool of pharma services (including in the areas of injectable, HPAPI etc.). The Company is also strengthening its presence in the Consumer Products segment in India.

PEL is listed on the BSE Limited and the National Stock Exchange of India Limited in India.